All In Biotech

Drug Trial Radar · NCT07128121

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of the Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Participants Aged 60 Years and Older

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 13, 2025

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Sponsor type
Industry
First posted
Aug 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.

Conditions

  • Respiratory Syncytial Virus (RSV) Infection

Interventions

  • Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)Biological

    Formulation for injection

  • PlaceboBiological

    0.9% sodium chloride (normal saline) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Local and Systemic Adverse Reactions Through 14 Days After Initial VaccinationTime frame: From initial vaccination up to14 days post initial vaccination
  2. Percentage of Participants With Unsolicited Adverse Events (AEs) Through 28 Days After Initial VaccinationTime frame: From initial vaccination up to 28 days post initial vaccination
  3. Percentage of Participants With Unsolicited AEs Through 30 Minutes After Initial VaccinationTime frame: From initial vaccination up to 30 minutes post initial vaccination
  4. Percentage of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) During StudyTime frame: Through study completion, about 3 years at most
  5. Percentage of Abnormal Results of Hematology On Day 3 After Initial Vaccination Compared with BaselineTime frame: From initial vaccination up to 3 days post initial vaccination
  6. Percentage of Abnormal Results of Clinical Chemistry On Day 3 After Initial Vaccination Compared with BaselineTime frame: From initial vaccination up to 3 days post initial vaccination
  7. Percentage of Abnormal Results of Coagulation On Day 3 After Initial Vaccination Compared with BaselineTime frame: From initial vaccination up to 3 days post initial vaccination
  8. Percentage of Participants With Any AEs Leading to Discontinuation of Vaccination or Withdrawal From The StudyTime frame: Through study completion, about 3 years at most
  9. Geometric mean concentration (GMC) for Pre-F Specific IgG Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
  10. Geometric Mean Fold Rise (GMFR) for Pre-F Specific IgG Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
  11. Seroconversion Rate (SCR) for Pre-F Specific IgG Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
  12. Geometric mean titer (GMT) for Neutralizing Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
  13. GMFR for Neutralizing Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination
  14. SCR for Neutralizing Antibody Against RSV A and RSV BTime frame: 1 month post-initial vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hunan Provincial Center for Disease Control and Prevention

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.